CoChat
Sign Up
Cited by 55Helminth infection and controlParasitic Diseases Research and TreatmentDermatological diseases and infestations

Treatment of dog thelaziosis caused by Thelazia callipaeda (Spirurida, Thelaziidae) using a topical formulation of imidacloprid 10% and moxidectin 2.5%

Bianciardi, P., Otranto, D.·2005·Veterinary Parasitology
DOI 10.1016/j.vetpar.2004.12.020
Open this paper in CoChat — free account

Abstract

Canine thelaziosis caused by Thelazia callipaeda infects dogs, cats, foxes, rabbits, and humans resulting in conjunctivitis, pain and excessive lacrimation. T. callipaeda live in the eyes under the nictitating membrane and females release first stage larvae which are ingested by flies which act as intermediate hosts. Control of canine thelaziosis is currently based on the removal of nematodes directly from the eyes of affected dogs or on the local instillation of antiparasitic drugs. With the aim of evaluating the efficacy against T. callipaeda of an association of imidacloprid 10% and moxidectin 2.5% by spot-on formulation administered via dermal application, three groups of naturally infected animals were selected: i.e. group A (21 dogs) received a single dose of imidacloprid 10% and moxidectin 2.5% by spot-on; group B (21 dogs) received a single dose of imidacloprid 10% by spot-on and group C (20 dogs) were left untreated. The efficacy of treatments was established by eye inspection and parasite viability and vitality after 1, 5 and 9 days after animal treatments (groups A and B) and after 9 days only in untreated animals (group C). Imidacloprid 10% and moxidectin 2.5% in spot-on formulation showed to be effective with regards the control of dog thelaziosis within 5 (90.47%) to 9 (95.23%) days after treatment. Only one dog from group A presented nematodes after treatment. The presence of parasites in the eyes of dogs from groups B (imidacloprid 10%) and C confirm that the anthelmintic efficacy against T. callipaeda in animal from group A (imidacloprid 10% and moxidectin 2.5%) was most likely attributable to moxidectin 2.5%. The spot-on formulation containing imidacloprid 10% and moxidectin 2.5% is very easy to apply and helps overcome problems linked to the mechanical removal of parasites or to the restraining of the animals for the local instillation of drugs in the eyes.

Integrity signals

Registry

Crossref · 10.1016/j.vetpar.2004.12.020

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Imidacloprid 10% and moxidectin 2.5% in spot-on formulation is effective for the control of dog thelaziosis within five to nine days after treatment, with efficacy of 90.47% to 95.23%.

    “Imidacloprid 10% and moxidectin 2.5% in spot-on formulation was also effective for the control of dog thelaziosis within five (90.47%) to nine (95.23%) days after treatment [120]”

    From Vector-borne helminths of dogs and humans in Europe (2013) · cites this paper as [120]

  • The formulation containing moxidectin and imidacloprid has the advantage of easy-to-apply dermal spot-on administration in parasitized dogs.

    “the formulation containing moxidectin and imidacloprid has the advantage of the easy-to-apply dermal spot-on administration in parasitized dogs [170]”

    From Pet roundworms and hookworms: A continuing need for global worming (2012) · cites this paper as [170]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Bianciardi, P., & Otranto, D.
Affiliations
University of Bari Aldo Moro (IT)
Corresponding author
Bianciardi, P.
ORCID
Otranto, D.
Venue
Veterinary Parasitology
Publisher
Elsevier BV
Published
2005-04
Volume
129
Issue
1-2
Pages
89-93
ISSN
0304-4017 (ISSN-L)
DOI
10.1016/j.vetpar.2004.12.020
OpenAlex
W1998349790
Cited by
55
References
24
Citations by year
2026: 2 · 2025: 3 · 2024: 2 · 2022: 5 · 2021: 6 · 2020: 3 · 2019: 4 · 2018: 1 · 2017: 1 · 2016: 5 · 2015: 2 · 2014: 2 · 2013: 4 · 2012: 6
FWCI
2.74
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Veterinary Parasitology (publishedVersion)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
Topics
  • Health Sciences › Veterinary › Small Animals › Helminth infection and control
  • Health Sciences › Medicine › Infectious Diseases › Parasitic Diseases Research and Treatment
  • Health Sciences › Medicine › Infectious Diseases › Dermatological diseases and infestations
Keywords
Thelazia callipaeda, imidacloprid, moxidectin, spot-on formulation, treatment efficacy, dogs, conjunctivitis, nictitating membrane, anthelmintic combination therapy
MeSH terms
Neonicotinoids, Administration, Topical, Animals, Anthelmintics, Dog Diseases, Dogs, Drug Combinations, Female, Imidazoles, Male, Nitro Compounds, Random Allocation, Thelazioidea, Eye Infections, Parasitic, Treatment Outcome, Spirurida Infections, Macrolides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review